HU-308 is primarily utilized in research settings to study its effects on the endocannabinoid system, particularly its role as a selective cannabinoid receptor type 2 (CB2) agonist. Its application is significant in exploring potential therapeutic avenues for inflammatory and neuropathic pain, as it modulates immune responses and reduces inflammation without the psychoactive effects associated with CB1 receptor activation. Additionally, HU-308 is investigated for its potential in treating conditions like osteoporosis, neurodegenerative diseases, and autoimmune disorders, where CB2 receptor activation may offer protective or regenerative benefits. Its use in preclinical studies helps in understanding the broader implications of CB2 signaling in various physiological and pathological processes.